Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7126 to 7140 of 8224 results

  1. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development Reference number: GID-TA11044 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development Reference number: GID-TA11344 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development Reference number: GID-TA11401 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-TA11569 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued Reference number: GID-TA11522

    Technology appraisal guidance
    Discontinued

  6. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

    Discontinued Reference number: GID-TA10783

    Technology appraisal guidance
    Discontinued

  8. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  9. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

    Technology appraisal guidance
    Discontinued

  10. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  11. Breathlessness

    Discontinued Reference number: GID-NG10387

    NICE guideline
    Discontinued

  12. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued

  13. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  14. Acute bowel obstruction

    Discontinued Reference number: GID-NG10377

    NICE guideline
    Discontinued

  15. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued